An innovative minimally invasive, active medical device platform for remote neurological monitoring of brain cancer patients to aid treatment/care

创新的微创主动医疗设备平台，用于对脑癌患者进行远程神经学监测，以帮助治疗/护理

• 批准号: 10099579
• 金额: $ 44.14万
• 依托单位: OPTO BIOSYSTEMS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10099579
• 关键词: innovative; minimally; invasive; active; medical

Opto is a UK-based medical device SME with a core project team of Dr Ben Woodington (CEO), Dr Elise Jenkins (Project Lead/CTO) and Jose Lepe (Product Lead).Electrical monitoring devices are crucial for managing neurological diseases such as brain cancer, epilepsy, and Parkinson's disease. These conditions affect around 105K people annually in the UK alone. Unfortunately, current technologies have made little headway with remote treatment, as they are invasive, uncomfortable and require hospital monitoring, which limits their use to short periods and restricts at-home use. This is problematic for two reasons. First, managing these diseases costs the NHS over £2B per year, and patients lose around £3B in productivity due to ongoing assessments. Secondly, infrequent, inconsistent 'snapshot' assessments of neurological health do not provide the full benefits of the technology, which could help guide treatment, inform disease progression and provide advance warning to patients.People who do not live near major hospitals with advanced facilities (~20 % of UK residents) and lower-income groups who lack the means to travel for treatment regularly are disproportionately affected by this.Opto has developed a minimally invasive, active medical technology platform that enables remote neurological monitoring of brain cancer patients to aid disease treatment and management. This innovation will improve the quality of life of patients suffering from neurological diseases, starting with brain cancer.

Opto是一家总部位于英国的医疗设备中小企业，其核心项目团队由Ben Woodington博士（首席执行官），Elise Jenkins博士（项目负责人/首席技术官）和Jose Lepe（产品负责人）组成。电子监测设备对于脑癌、癫痫和帕金森氏症等神经系统疾病的治疗至关重要。仅在英国，每年就有大约10.5万人受到这些疾病的影响。不幸的是，目前的技术在远程治疗方面进展甚微，因为它们是侵入性的，不舒服的，需要医院监测，这限制了它们的使用时间很短，限制了家庭使用。这有两个问题。首先，管理这些疾病每年要花费NHS超过20亿英镑，而由于持续的评估，患者的生产力损失约30亿英镑。其次，对神经系统健康的不频繁、不一致的“快照”评估并不能提供这项技术的全部好处，而这项技术可以帮助指导治疗、告知疾病进展并向患者提供提前警告。居住在拥有先进设施的大医院附近的人（约占英国居民的20%）和缺乏定期前往治疗手段的低收入群体受到的影响尤为严重。Opto开发了一种微创、主动的医疗技术平台，可以对脑癌患者进行远程神经监测，以帮助疾病的治疗和管理。这项创新将从脑癌开始，改善神经系统疾病患者的生活质量。